FORMULATION AND EVALUATION OF TACROLIMUS LOADED TRANSFERSOMAL SUBLINGUAL FILMS FOR EFFICIENT MANAGEMENT OF ORGAN REJECTION: IN VITRO AND IN VIVO STUDY

SUMA R.; PREETI V. KARWA; KUSUM DEVI V.

doi:10.22159/ijap.2023v15i6.48780

Authors

SUMA R. Department of Pharmaceutics, Al-Ameen College of Pharmacy, Bengaluru, Karnataka, India https://orcid.org/0000-0002-5433-6293
PREETI V. KARWA Department of Pharmaceutics, Al-Ameen College of Pharmacy, Bengaluru, Karnataka, India https://orcid.org/0000-0002-3367-5237
KUSUM DEVI V. Nitte College of Pharmaceutical Sciences, Bangalore, Karnataka, India

DOI:

https://doi.org/10.22159/ijap.2023v15i6.48780

Keywords:

Organ transplantation, Tacrolimus, Transfersomes, Nanovesicles, Sublingual films, Nephrotoxicity

Abstract

Objective: Patients travailing with end-stage organ failure can benefit from a life-saving treatment protocol called organ transplantation that also rallies eminence of life. Tacrolimus plays an important role in maintaining the healthy status of the organ transplanted, but its widespread clinical application is constrained due to low oral bioavailability which can be the limiting factor for the reduction in life span of transplanted healthy organ.

Methods: To overcome the drawbacks of tacrolimus and to maximize its therapeutic efficiency, tacrolimus was formulated as transfersomes using thin film hydration method using soyalecithin and Tween-80, optimized by Central composite designs and characterized for Particle size, deformability index (DI), entrapment efficiency(EE%) and Zeta potential. The selected transfersome formulation was incorporated into sublingual films using Hydroxy Propyl Methyl Cellulose (HPMC) as a film-forming polymer and Polyethylene Glycol (PEG-400) as Plasticizer. The physical characteristics (average weight, pH, uniformity of weight and thickness) of the prepared films were studied, in addition they were evaluated for the in vitro drug release, ex vivo permeation, Differential Scanning Calorimetry (DSC), Attenuated Reflectance Spectroscopy (ATR), Scanning Electronic Microscopy (SEM), stability and in vivo pharmacokinetics in rats to prove the effect of flexibility provided by vesicle formation through sublingual route for enhanced systemic availability of tacrolimus.

Results: Designed and optimized transfersomal vesicles showed the vesicle size of 139±2.1 nm with a Deformability Index of 8.53±1.9%, Entrapment Efficiency of 86.66±1.2% and zeta potential of-23.6 mV respectively. Optimized Tacrolimus-loaded transfersomal vesicles (TAC-TFs) showed controlled release with more than 80±3.4% for an extended period of time compared to pure drug Tacrolimus. The average weight of all prepared transfersomal sublingual film (TAC_TF_SL films), batches were found in the range of 55.8±1.45 to 94.2±1.42 mg with mean thickness in the range of 0.23+0.1 to 0.52±0.2 mm indicating uniform cast of respective batches. The surface pH was found to be in the range of 6.9 to 7.0 which was close to saliva pH.

Optimized transfersomal sublingual films as well as nanovesicular dispersions found to be followed Zero order diffusion coupled with polymer relaxation. Ex vivo studies revealed the improved permeation of 6.51±0.04µg drug through sublingual mucosa than pure drug of 1.2±0.01 µg, depicting the significant role of soyalecithin and edge activator in the formulations. Transfersomal sublingual films exhibited controlled release with higher plasma concentration of 9.16±2.34 µg/ml at Tmax of 1.29±1.51h in comparison with 7.99±1.23 µg/ml at Tmax of 0.75±1.78h (oral marketed dosage form Pengraf capsules) embarking the higher rate of controlled absorption after sublingual delivery of optimized sublingual films with significant increase in AUC of 129.87±2.40 μg/ml/h when compared to AUC of marketed dosage form of 69.19±1.46 μg/ml/h. In addition, the absolute bioavailability of the drug following sublingual administration was found to be 70.77±2.92% in comparison with that after oral administration 40.60±2.34%.

Conclusion: Designed Tacrolimus loaded transfersomal sublingual films can be a promising carrier for delivering tacrolimus through sublingual route by enhancing drug bioavailability efficiently, which can be a boon to organ-transplanted patients.

Downloads

Download data is not yet available.

References

Baldwin WM, Valujskikh A, Fairchild RL. Mechanisms of antibody-mediated acute and chronic rejection of kidney allografts. Curr Opin Organ Transplant. 2016 Feb;21(1):7-14. doi: 10.1097/MOT.0000000000000262, PMID 26575854.

Lin CM, Gill RG. Direct and indirect allograft recognition: pathways dictating graft rejection mechanisms. Curr Opin Organ Transplant. 2016 Feb;21(1):40-4. doi: 10.1097/MOT.0000000000000263, PMID 26575853.

Boix F, Millan O, San Segundo D, Mancebo E, Miras M, Rimola A. Activated regulatory t cells expressing CD4(+)CD25(high)CD45RO(+)CD62L(+) biomarkers could be a risk factor in liver allograft rejection. Transplant Proc. 2015 Oct;47(8):2380-1. doi: 10.1016/j.transproceed.2015.09.007, PMID 26518933.

Sanchez Fueyo A, Strom TB. Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs. Gastroenterology. 2011 Jan;140(1):51-64. doi: 10.1053/j.gastro.2010.10.059, PMID 21073873.

Rath T. Tacrolimus in transplant rejection. Expert Opin Pharmacother. 2013 Jan;14(1):115-22. doi: 10.1517/14656566.2013.751374, PMID 23228138.

Wang YP, Gan Y, Zhang XX. Novel gastroretentive sustained-release tablet of tacrolimus based on self-microemulsifying mixture: in vitro evaluation and in vivo bioavailability test. Acta Pharmacol Sin. 2011 Oct;32(10):1294-302. doi: 10.1038/aps.2011.90, PMID 21927013.

Patel P, Patel H, Panchal S, Mehta T. Formulation strategies for drug delivery of tacrolimus: an overview. Int J Pharm Investig. 2012 Oct-Dec;2(4):169-75. doi: 10.4103/2230-973X.106981, PMID 23580932.

Roy JN, Barama A, Poirier C, Vinet B, Roger M. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics. 2006 Sep;16(9):659-65. doi: 10.1097/01.fpc.0000220571.20961.dd, PMID 16906020.

Srinivas NR. Letter: sublingual dosing of tacrolimus in transplant patients-interesting concept to overcome first pass effects. Aliment Pharmacol Ther. 2017;46(1):79-80. doi: 10.1111/apt.14087, PMID 28589592.

Aull MJ. Pharmacokinetics of sublingual versus oral tacrolimus in patients awaiting kidney transplantation. Clin Trials Gov. 2017 Dec 12;18(4):345-56.

Solari S, Cancino A, Wolff R, Norero B, Vargas JI, Barrera F. Sublingual tacrolimus administration provides similar drug exposure to per-oral route employing lower doses in liver transplantation: a pilot study. Aliment Pharmacol Ther. 2017 Jan;45(9):1225-31. doi: 10.1111/apt.14022, PMID 28261844.

Federico S, Carrano R, Sabbatini M, Nappi R, Russo L, Apicella L. Sublingual administration improves systemic exposure of tacrolimus in kidney transplant recipients: comparison with oral administration. Eur J Clin Invest. 2016 Jul;46(7):651-7. doi: 10.1111/eci.12644, PMID 27240092.

Narang N, Sharma J. Sublingual mucosa as a route for systemic drug delivery. A review. Int J Pharm. 2011;3Suppl 2:123-9.

Pennington CA, Park JM. Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients. Am J Health Syst Pharm. 2015 Feb;72(4):277-84. doi: 10.2146/ajhp140322, PMID 25631834.

Jain S, Tiwary AK, Sapra B, Jain NK. Formulation and evaluation of ethosomes for transdermal delivery of lamivudine. AAPS PharmSciTech. 2007 Oct;8(4):E111. doi: 10.1208/pt0804111, PMID 18181532.

Gillet A, Lecomte F, Hubert P, Ducat E, Evrard B, Piel G. Skin penetration behaviour of liposomes as a function of their composition. Eur J Pharm Biopharm. 2011 Jun 15;79(1):43-53. doi: 10.1016/j.ejpb.2011.01.011, PMID 21272638.

Song CK, Balakrishnan P, Shim CK, Chung SJ, Chong S, Kim DD. A novel vesicular carrier, transethosome, for enhanced skin delivery of voriconazole: characterization and in vitro/in vivo evaluation. Colloids Surf B Biointerfaces. 2012 Apr 1;92:299-304. doi: 10.1016/j.colsurfb.2011.12.004, PMID 22205066.

Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochim Biophys Acta. 1992 Feb 17;1104(1):226-32. doi: 10.1016/0005-2736(92)90154-e, PMID 1550849.

El Maghraby GM, Williams AC, Barry BW. Interactions of surfactants (edge activators) and skin penetration enhancers with liposomes. Int J Pharm. 2004 Jun 12;276(1-2):143-61. doi: 10.1016/j.ijpharm.2004.02.024, PMID 15113622.

Elkomy MH, El Menshawe SF, Abou Taleb HA, Elkarmalawy MH. Loratadine bioavailability via buccal transferosomal gel: formulation, statistical optimization, in vitro/in vivo characterization, and pharmacokinetics in human volunteers. Drug Deliv. 2017 Nov;24(1):781-91. doi: 10.1080/10717544.2017.1321061, PMID 28480758.

Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes–novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release. 2000;65 Suppl 3:403-18. doi: 10.1016/s0168-3659(99)00222-9, PMID 10699298.

Elsayed MM, Abdallah OY, Naggar VF, Khalafallah NM. Deformable liposomes and ethosomes: mechanism of enhanced skin delivery. Int J Pharm. 2006;322(1-2):60-6. doi: 10.1016/j.ijpharm.2006.05.027, PMID 16806755.

Elmenshawe SF, Kharshom RM, Khames A. Preparation and optimization of buccal proponolol hydrochloride nanoethosomal gel: a novel approach for enhancement of bioavailability. J Nanomed Nanotechnol. 2017 Jan;8(3):435.

Allam A, Fetih G. Sublingual fast dissolving niosomal films for enhanced bioavailability and prolonged effect of metoprolol tartrate. Drug Des Devel Ther. 2016 Aug 2;10(3):2421-33. doi: 10.2147/DDDT.S113775, PMID 27536063.

Moolakkadath T, Aqi M, Ahad A. Sarim Imam S. Development of transethosomes formulation for dermal fisetin delivery: box–behnkendesign, optimization, in vitro skin penetration, vesicles–skin interaction and dermatokinetic studies. Artif Cells Nanomed Biotechnol. 2018 May 7;1(2):345-72.

Le NTT, Cao VD, Nguyen TNQ, Le TTH, Tran TT, Hoang Thi TT. Soy lecithin-derived liposomal delivery systems: surface modification and current applications. Int J Mol Sci. 2019 Oct;20(19):4706. doi: 10.3390/ijms20194706, PMID 31547569.

Ahad A, Al-Saleh AA, Al-Mohizea AM, Al-Jenoobi FI, Raish M, Yassin AEB. Formulation and characterization of novel soft nanovesicles for enhanced transdermal delivery of eprosartan mesylate. Saudi Pharm J. 2017 Nov;25(7):1040-6. doi: 10.1016/j.jsps.2017.01.006, PMID 29158713.

Singh S, Vardhan H, Kotla NG, Maddiboyina B, Sharma D, Webster TJ. The role of surfactants in the formulation of elastic liposomal gels containing a synthetic opioid analgesic. Int J Nanomedicine. 2016 Apr 8;11(2):1475-82. doi: 10.2147/IJN.S100253, PMID 27114707.

Yusuf M, Sharma V, Pathak K. Nanovesicles for transdermal delivery of felodipine: development, characterization, and pharmacokinetics. Int J Pharm Investig. 2014 Jul-Sep;4(3):119-30. doi: 10.4103/2230-973X.138342, PMID 25126525.

Aujla M, Rana AC, Bala R. Comparative potential of vesicular carriers for transdermal drug delivery: a review. Res J Pharm Technol. 2012 Mar;5:302-6.

Zheng WS, Fang XQ, Wang LL, Zhang YJ. Preparation and quality assessment of itraconazole transfersomes. Int J Pharm. 2012 Oct 15;436(1-2):291-8. doi: 10.1016/j.ijpharm.2012.07.003, PMID 22796030.

Astuti KF, Surini S, Bahtiar A. Advances in ameliorating rheumatoid arthritis by andrographolide ethosome-based gel: pharmacokinetic and activity study in rats. Int J App Pharm. 2023;15(1):79-86. doi: 10.22159/ijap.2023v15i1.46350.

Bezabeh MF, Werbovetz KA, Murthy KVR. Formulation and evaluation of amphotericin B and miltefosine combination nanovesicles. Int J App Pharm. 2021;13(3):74-8. doi: 10.22159/ijap.2021v13i3.40605.

Surini S, Nastiti PD, Putri AR, Putri KS. Formulation of andrographolide transfersomes gel for transdermal delivery: a preliminary study. Int J App Pharm 2020;12(1):187-91. doi: 10.22159/ijap.2020.v12s1.FF043.

Jain S, Patel N, Shah MK, Khatri P, Vora N. Recent advances in lipid-based vesicles and particulate carriers for topical and transdermal application. J Pharm Sci. 2017;106(2):423-45. doi: 10.1016/j.xphs.2016.10.001, PMID 27865609.

Elshafeey AH, El-Dahmy RM. Formulation and development of oral fast-dissolving films loaded with nanosuspension to augment paroxetine bioavailability: in vitro characterization, ex vivo permeation, and pharmacokinetic evaluation in healthy human volunteers. Pharmaceutics. 2021 Nov;13(11):1869. doi: 10.3390/pharmaceutics13111869, PMID 34834284.

Zaman M, Hanif M, Qaiser AA. Effect of polymer and plasticizer on thin polymeric buccal films of meloxicam designed by using central composite rotatable design. Acta Pol Pharm. 2016 Sep;73(5):1351-60. PMID 29638075.

Londhe V, Shirsat R. Formulation and characterization of fast-dissolving sublingual film of iloperidone using box-behnken design for enhancement of oral bioavailability. AAPS PharmSciTech. 2018 Apr;19(3):1392-400. doi: 10.1208/s12249-018-0954-y, PMID 29396734.

Shaji J, Lal M. Preparation, optimization and evaluation of transferosomal formulation for enhanced transdermal delivery of a cox-2 inhibitor. Int J Pharm Pharm Sci. 2013 Nov;6(1):467-77.

Siddiqui MHB, Islam MS, Razu MR, Zaman AN, Jadi B, Saha T. Preparation and evaluation of sublingual film of ketorolac tromethamine. Drug Dev Ind Pharm. 2022 Sep;48(9):438-45. doi: 10.1080/03639045.2022.2123925, PMID 36094414.

Wadetwar RN, Ali F, Kanojiya P. Formulation and evaluation of fast dissolving sublingual film of paroxetine hydrocholride for treatment of depression. AJPCR. 2019 Oct;12(10):126-32.

Honeywell Nguyen PL, Bouwstra JA. The in vitro transport of pergolide from surfactant-based elastic vesicles through human skin: a suggested mechanism of action. J Control Release. 2003 Jan 9;86(1):145-56. doi: 10.1016/s0168-3659(02)00415-7, PMID 12490380.

Amano O, Mizobe K, Bando Y, Sakiyama K. Anatomy and histology of rodent and human major salivary glands: overview of the Japan salivary gland society-sponsored workshop. Acta Histochem Cytochem. 2012 Oct 31;45(5):241-50. doi: 10.1267/ahc.12013, PMID 23209333.